In a phase 1b clinical trial, TG02 was administered alone or in combination with pembrolizumab to patients with locally advanced primary or recurrent KRAS codon 12 or 13 (exon 2) mutant CRC (NCT02933944). This evidence concerns the gene KRAS and colorectal carcinoma.